Hong, S.H.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 131

The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

Kim, H., Lee, J. E., Hong, S. H., Lee, M. A., Kang, J. H., & Kim, I.-H. (2019) · BMC Cancer

Cancer Immunotherapy and BiomarkersNeutropenia and Cancer Infections

Cited by 72